Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.
DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS
申请人:Jones Simon
公开号:US20100286136A1
公开(公告)日:2010-11-11
The invention provides methods of using dihydronaphthyridinyl and related compounds to treat opthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.
[EN] CARBOXAMID? COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS<br/>[FR] COMPOSÉS À BASE DE CARBOXAMIDE ET LEUR UTILISATION EN TANT QU'AGONISTES DU RÉCEPTEUR DES CHIMIOKINES
申请人:EPIX DELAWARE INC
公开号:WO2009076512A1
公开(公告)日:2009-06-18
Chemokine receptor antagonists, in particular, compounds of Formula (I- A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.